临床前数据,BGB-15025 可增加PMBC 中IL-2的产生; CT26WT 同源模型中联用PD-1 抗体,低至1 mg·kg -1 也可表现出显著的联用效果: 68%的肿瘤体积小于100 mm3,28% 达到无瘤状态; 初步毒理研究还表明BGB-15025 治疗窗较宽,约20 ～ 50 倍。 4、XYF19 XYF19是一款新型CD19 CAR-T细胞治疗产品,基于因明生...
2021年5月,BGB-15025胶囊临床申请正式获NMPA受理,用于治疗实体瘤,标志着百济神州真正意义上的第一款自主研发潜在first-in-class的药物进入临床阶段。临床前数据,BGB-15025 可增加PMBC 中IL-2的产生; CT26WT 同源模型中联用PD-1 抗体,低至1 mg·kg -1 也可表现出显著的联用效果: 68%的肿瘤体积小于100 mm3,28...
此外,在本次ASCO会议上,宇繁生物还将介绍其关于Cbl-b抑制剂YF550-C1的相关研究数据。Casitas B系淋巴瘤b(Cbl-b)是E3泛素家族中的连接酶之一,主要表达于成熟造血细胞,包括T细胞和NK细胞。即使没有CD28共刺激因子的作用,敲除Cbl-b也会在TCR激活期间...
临床前数据,BGB-15025 可增加PMBC 中IL-2的产生; CT26WT 同源模型中联用PD-1 抗体,低至1 mg·kg -1 也可表现出显著的联用效果: 68%的肿瘤体积小于100 mm3,28% 达到无瘤状态; 初步毒理研究还表明BGB-15025 治疗窗较宽,约20 ～ 50 倍。 4、XYF19 XYF19是一款新型CD19 CAR-T细胞治疗产品,基于因明...
Oral administration of BGB-15025 demonstrates dose-dependent pSLP76 inhibition in splenic T cells and induces serum IL-2 in mouse model. In efficacy studies, BGB-15025 exhibits anti-tumor activity in GL261 tumor model as single agent. Moreover, BGB-15025 demonstrated combination effect with anti...
in the Certificate of Analysis.BIOLOGICAL ACTIVITY生物活性HPK1-IN-33 (compound 21) 是一种有效的造血祖细胞激酶 1 (HPK1) 抑制剂,Ki 值为 1.7 μM。HPK1-IN-33 抑制IL-2 的产生,在 Jurkat WT 和 Jurkat HPK1 KO 细胞中的 EC50 分别为 286 和 >100 ...
With the stimulation of CD3/CD28, boost of IL-2 production was observed in Jurkat cells, purified human T cells, and human peripheral blood mononuclear cells upon treatment of BB3008 at sub-micromolar concentration. BB3008 also enhanced the killing activity of T cell against EL4 lymphoma cell ...
Notably, compound 24 exhibited enhanced potency in promoting IL-2 secretion in Jurkat T cells, reduced cellular toxicity, and improved liver microsomal stability compared to hit 9 . Overall, this study provides a promising lead compound for further optimization as a candidate for cancer immunotherapy...
临床前数据,BGB-15025 可增加PMBC 中IL-2的产生; CT26WT 同源模型中联用PD-1 抗体,低至1 mg·kg -1 也可表现出显著的联用效果: 68%的肿瘤体积小于100 mm3,28% 达到无瘤状态; 初步毒理研究还表明BGB-15025 治疗窗较宽,约20 ～ 50 倍。 4、XYF19...
Results HPK1 inhibitors exhibited a potent, concentration-dependent reduction in pSLP-76, with a concurrent increase in IL-2 secretion in both Jurkat and human CD8+ T cells. Human T cells also demonstrated increased IFN-纬 and TNF-伪 secretion as well as a greater percentage of activated CD...